# Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes

**Authors:** Annalisa Ciabattini, Gennaro Prota, Dennis Christensen, Peter Andersen, Gianni Pozzi, Donata Medaglini

PMC · DOI: 10.3389/fimmu.2015.00430 · Frontiers in Immunology · 2015-08-28

## TL;DR

This study shows that combining different vaccine delivery methods and adjuvants can enhance immune responses, particularly in the lungs.

## Contribution

The study identifies optimal prime-boost strategies using CAF01 and CpG adjuvants for inducing strong CD4+ T cell responses.

## Key findings

- SC priming with H56 and CAF01 followed by nasal boosting with H56 and CpG led to the greatest CD4+ T cell expansion in spleen and lungs.
- Nasal boosting recruited more CD4+ T cells to the lungs when priming was done subcutaneously.
- Parenterally primed CD4+ T cells responded to booster immunization, unlike nasally primed cells.

## Abstract

The design of heterologous prime-boost vaccine combinations that optimally shape the immune response is of critical importance for the development of next generation vaccines. Here, we tested different prime-boost combinations using the tuberculosis vaccine antigen H56 with CAF01 or CpG ODN 1826 adjuvants, administered by the parenteral and nasal routes. Using peptide-MHC class II tetramers, antigen-specific CD4+ T cells were tracked following primary and booster immunizations. Both parenteral priming with H56 plus CAF01 and nasal priming with H56 plus CpG elicited significant expansion of CD4+ tetramer-positive T cells in the spleen; however, only parenterally primed cells responded to booster immunization. Subcutaneous (SC) priming with H56 and CAF01 followed by nasal boosting with H56 and CpG showed the greater expansion of CD4+ tetramer-positive T cells in the spleen and lungs compared to all the other homologous and heterologous prime-boost combinations. Nasal boosting exerted a recruitment of primed CD4+ T cells into lungs that was stronger in subcutaneously than nasally primed mice, in accordance with different chemokine receptor expression induced by primary immunization. These data demonstrate that SC priming is fundamental for eliciting CD4+ T cells that can be efficiently boosted by the nasal route and results in the recruitment of antigen-experienced cells into the lungs. Combination of different vaccine formulations and routes of delivery for priming and boosting is a strategic approach for improving and directing vaccine-induced immune responses.

## Linked entities

- **Chemicals:** H56 (PubChem CID 81345)
- **Diseases:** tuberculosis (MONDO:0018076)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, Tlr9 (toll-like receptor 9) [NCBI Gene 81897], Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Clec4e (C-type lectin domain family 4, member e) [NCBI Gene 56619] {aka Clecsf9, Mincle}, FCGR2A (Fc gamma receptor IIa) [NCBI Gene 2212] {aka CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, Ccr6 (C-C motif chemokine receptor 6) [NCBI Gene 12458] {aka CC-CKR-6, CCR-6, Cmkbr6, KY411}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, Cxcr3 (C-X-C motif chemokine receptor 3) [NCBI Gene 12766] {aka Cd183, Cmkar3}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, Tbx21 (T-box 21) [NCBI Gene 57765] {aka TBT1, Tbet, Tblym}
- **Diseases:** M. tuberculosis infection (MESH:D014376), infection (MESH:D007239)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773], Mus musculus (house mouse, species) [taxon 10090], Halobacillus sp. 56 (species) [taxon 670858]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4551867/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4551867/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC4551867/full.md

---
Source: https://tomesphere.com/paper/PMC4551867